Pharmaceutical Technology

MAY 10, 2024

Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine.

Licensing 130

Licensing Licensing Vaccine Vaccination 130

Bio Pharma Dive

MAY 13, 2024

The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”

Licensing 188

Licensing Licensing Vaccination Vaccine 188

World of DTC Marketing

SEPTEMBER 10, 2021

The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. It is reckless at this point for the government not to mandate vaccination.

Vaccine 191

Vaccine Vaccination Licensing Licensing 191

Fierce Pharma

FEBRUARY 24, 2023

Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license esagonowsky Fri, 02/24/2023 - 09:18

Licensing 145

Licensing Licensing Vaccine Vaccination 145

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccine 195

Vaccine Vaccination Immune Response Bacteria 195

pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. One of the primary advantages of this approach is that the oral vaccine capsules are stable at room temperature, which means they do not require cold chain storage.

Licensing 119

Licensing Licensing Vaccine Vaccination 119

Bio Pharma Dive

AUGUST 6, 2020

The Serum Institute, one of the world's largest vaccine producers, licensed Novavax's experimental shot, while Wockhardt signed on with the U.K. to help make AstraZeneca's candidate.

Vaccine 162

Vaccine Vaccination Manufacturing Licensing 162

Pharmaceutical Technology

JULY 3, 2024

GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.

Vaccine 130

Vaccine Vaccination Development Licensing 130

NY Times

AUGUST 20, 2021

Federal regulators are winding down the process of licensing Pfizer’s two-dose coronavirus vaccine, setting up an approval possibly by Monday and possibly kicking off a wave of new mandates.

Vaccine 145

Vaccine Vaccination Licensing Licensing 145

Pharmaceutical Technology

NOVEMBER 8, 2024

LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority of Pakistan (DRAP) seeking conditional approval for its PIKA Rabies Vaccine for post-exposure prophylaxis (PEP).

Vaccine 130

Vaccine Vaccination Licensing Licensing 130

Bio Pharma Dive

JULY 20, 2023

The startup will take on development of a shigellosis vaccine GSK inherited when it acquired LimmaTech’s predecessor, GlycoVaxyn, in 2015.

Vaccine 130

Vaccine Vaccination Licensing Licensing 130

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

pharmaphorum

MAY 10, 2024

Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2

Vaccine 115

Vaccine Vaccination Licensing Licensing 115

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccine 130

Vaccine Vaccination Development Immune Response 130

STAT News

AUGUST 9, 2022

heath secretary recently declared monkeypox as a public health emergency , paving the way for emergency use authorizations of additional vaccines or vaccine regimens to fight the disease. The same day, Food and Drug Administration Commissioner Robert Califf said that the U.S. — by changing the way it is given.

Vaccination 105

Vaccination Vaccine Licensing Licensing 105

BioSpace

JUNE 10, 2024

Moderna’s combination vaccine candidate for COVID-19 and influenza outperformed licensed vaccines in older adults, according to late-stage results reported on Monday.

Vaccine 107

Vaccine Vaccination Licensing Licensing 107

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works. Regarding the BA.4

Vaccine 138

Vaccine Vaccination Development Immune Response 138

pharmaphorum

AUGUST 1, 2024

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's (..)

Vaccine 105

Vaccine Vaccination Pharma Companies Licensing 105

Pharmaceutical Technology

AUGUST 23, 2022

5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.

Vaccine 130

Vaccine Vaccination Gene Therapy Protein 130

World of DTC Marketing

FEBRUARY 11, 2022

Pfizer has held a vaccine monopoly, blocking low-income countries from accessing its novel technology, while enriching shareholders at levels advocates for vaccine equity label “obscene.” Sure they developed a vaccine but isn’t it a moral responsibility to share it with the world? The Atlantic ). How much profit is enough?

Vaccination 212

Vaccination Vaccine Sales Licensing 212

BioPharma Reporter

MAY 6, 2021

The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month. Moderna has reported the first profitable quarter in the companyâs history: after 10 years of research and several billion dollars of investment in its mRNA platform.

Licensing 94

Licensing Licensing Vaccine Vaccination 94

STAT News

OCTOBER 12, 2022

Merck on Wednesday agreed to extend an ongoing collaboration with Moderna to develop a personalized vaccine for the treatment of patients with skin cancer. Moderna is getting $250 million from Merck to secure opt-in rights to the cancer vaccine candidate, called mRNA-4157.

Vaccine 98

Vaccine Vaccination Licensing Licensing 98

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

Medical Xpress

FEBRUARY 3, 2023

A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. The new vaccine, VSV-SUDV, completely protected cynomolgus macaques against a lethal SUDV challenge.

Vaccine 98

Vaccine Vaccination Licensing Licensing 98

Bio Pharma Dive

MAY 13, 2022

The agreement, which covers three experimental vaccines as well as several key patents, will be royalty free for products sold in 49 low-income countries.

Licensing 148

Licensing Licensing Vaccination Vaccine 148

BioPharma Reporter

FEBRUARY 21, 2023

The US Food and Drug Administration (FDA) has accepted Pfizerâs Biologics License Application (BLA) for its maternal RSV vaccine under priority review. If approved, the vaccine will become the first RSV vaccine for pregnant women to protect against RSV in infants.

Vaccine 98

Vaccine Vaccination Licensing Licensing 98

STAT News

APRIL 24, 2023

Marburg could soon become the second virus in the past year to have experimental vaccine candidates ready for testing under an emergency use listing. Until this point, no licensed vaccines or treatments are available for Marburg. Read the rest…

Vaccine 111

Vaccine Vaccination Containment Licensing 111

Pharmaceutical Technology

OCTOBER 7, 2024

mRNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in precision medicine.

Licensing 130

Licensing Licensing Protein Vaccination 130

pharmaphorum

SEPTEMBER 15, 2022

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than shots made using traditional cell culture or recombinant techniques. It will compare the shot against a licensed inactivated vaccine.

Vaccine 104

Vaccine Vaccination Trials Development 104

XTalks

APRIL 18, 2022

Top COVID-19 mRNA vaccine maker BioNTech is setting out to explore new and improved delivery technologies for mRNA vaccines, recently announcing a collaboration with New Jersey-based lipid nanocrystal developer Matinas BioPharma. Related: BioNTech Unveils the BioNTainer, a Modular mRNA Vaccine Factory to Help Production in Africa.

Vaccine 105

Vaccine Vaccination Development Immune Response 105

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

BioPharma Reporter

JULY 19, 2021

The US Food and Drug Administration (FDA) has granted priority review designation for Pfizer and BioNTechâs COVID-19 vaccine Biologics License Application (BLA).

Vaccine 98

Vaccine Vaccination Licensing Licensing 98

Bio Pharma Dive

NOVEMBER 2, 2022

The drugmaker agreed to pay $200 million upfront and potentially billions more to license the technology and knowhow from Arcturus to make preventive shots for COVID-19, influenza and other respiratory infections.

Licensing 148

Licensing Licensing Vaccination Vaccine 148

pharmaphorum

OCTOBER 7, 2021

Moderna has said it plans to invest $500 million in a new facility for manufacturing mRNA vaccines in Africa, and has kicked off a search to find a suitable country and location. of Africans have been fully vaccinated against COVID-19, and just 15 African nations have met the agency’s objective of 10% coverage.

Vaccine 98

Vaccine Vaccination Manufacturing Packaging 98

Pharma Times

SEPTEMBER 2, 2021

Jab aimed at adults aged 50 years and older and those at increased risk

Licensing 113

Licensing Licensing Vaccination Vaccine 113

BioSpace

JUNE 5, 2022

GSK's MMR vaccine is only the second to be approved in the United States for protection against measles, mumps and rubella. The first, licensed to Merck, was approved in 1971.

FDA Approval 96

FDA Approval Vaccine Vaccination Licensing 96

BioPharma Reporter

DECEMBER 8, 2022

The US Food and Drug Administration (FDA) has accepted Pfizerâs RSV vaccine Biologics License Application (BLA) for priority review: with a decision expected in May.

Vaccine 98

Vaccine Vaccination Licensing Licensing 98